Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer

Immunotherapy has shown modest activity in metastatic breast cancer (MBC). In this phase I dose escalation study, we assessed safety of tremelimumab, a humanized anti-CTLA4 monoclonal antibody, at starting dose 3 mg/kg, on the third day of palliative radiotherapy (2000cGy in 5 daily fractions) in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Di (Maria), Fyles, Anthony, Nguyen, Linh T., Neel, Benjamin G., Sacher, Adrian, Rottapel, Robert, Wang, Ben X., Ohashi, Pamela S., Sridhar, Srikala S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508206/
https://www.ncbi.nlm.nih.gov/pubmed/31105877
http://dx.doi.org/10.18632/oncotarget.26893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508206/
https://www.ncbi.nlm.nih.gov/pubmed/31105877
http://dx.doi.org/10.18632/oncotarget.26893

Ejemplares similares